Corning Jerry's published phase II clinical data on KN046's treatment of non-small cell lung cancer

The World Lung Cancer Congress (WCLC) is the world's largest multidisciplinary oncology conference dedicated to lung cancer and other chest malignancies.
2020 World Lung Cancer Congress (WCLC 2020 Virtual Conference) will be held from 28 to 31 January 2021.
the two studies published by Corninger will be presented in the form of wall reports and mini-oral reports, respectively.
KN046's Phase II clinical study data for the treatment of patients with advanced non-small cell lung cancer (NSCLC) KN046-201 is a Phase II, open, multi-center clinical study designed to assess the effectiveness, safety, and tolerance of KN046 in patients with advanced non-small cell lung cancer.
group of 64 patients with NSCLC who had previously received first-line systemic treatment, The results showed that KN046 tolerance was good and effective as a second-line treatment for advanced NSCLC, showing no progressive lifetime (PFS) and total lifetime (OS) benefits in non-small cell lung cancer: 13 months for medium follow-up and 3.68 months for medium non-progressive survival (95% CI 3.35, 7. 29): sq-NSCLC and non-sq NSCLC were 7.29 months (3.68, 9.23) and 3.58 months (2.46, 5.52), respectively;
advantage over the historical data of PD(L)-1 antibodies.
safety, 24 out of 64 patients (37.5%) experienced level ≥3 TRAE, mainly infusion reactions (10.9%), anemia (4.7%), drug-based liver damage (3.1%), abnormal liver function (3.1%), and lung infections (3.1%).
irAE was mainly neophil count decrease (3.1%), white blood cell count decreased (3.1%).
"Lung cancer is the most common malignant tumor in the world and China, and is the main cause of tumor death, with non-small cell lung cancer (NSCLC) accounting for 80 to 85 percent of lung cancer, and the treatment status quo needs to be improved urgently," said Professor Zhou Caisan, director of oncology at Shanghai Lung Hospital affiliated with Tongji University and lead researcher of the clinical trial.
and safety data from KN046-201 suggest that it has the potential to be an important treatment option for patients with advanced NSCLC.
We look forward to further exploring the advantages of KN046 in Phase III. Research to provide a new standard first-line solution for the treatment of advanced non-small cell lung cancer for the benefit of more patients.
" KN046 Preliminary Safety and Effectiveness Results in Patients with Rare Chest Tumors In a Phase I Clinical Study (KN046-AUS-001) conducted in Australia, 5 patients with rare chest tumors were included in the group, including 4 cases of thymus epithelia (2 cases of thymus cancer (IV.stage), 2 cases of thymus tumor (IV.stage) and 1 case of thymus interstity tumor (sarcoma, phase III.B
duration of treatment was 22.7 weeks (range: 16-48).
KN046 in the thymus epithyroid tumor confirmed disease relief rate of 50%, confirmed and unrefirmed disease relief rate of 75% (2 confirmed PR, 1 case not confirmed PR), disease control rate of 100%.
3 out of 5 patients had 14 immuno-related adverse events, most of which were level 1-2, and only 1 subject had 2 secondary level 3 treatment-related adverse events (autoimmune hepatitis and elevated ALT).
Professor Gary Richardson, lead researcher on the trial, said: "The treatment of thymus epithal tumours is limited and new treatment options are urgently needed.
KN046 showed 75 percent disease relief and 100 percent disease control in patients with thymus epithal tumors, which is significant for patients with rare chest tumors, especially those with difficult surgery or chemotherapy.
we look forward to this clinical data driving research into dual-specific antibody immunotherapy in the treatment of rare tumors in the chest, bringing new hope to patients around the world.
" About KN046 KN046 is Corning Jerry's self-developed PD-L1/CTLA-4 dual-specific antibodies, whose innovative design includes: the use of different mechanisms of CTLA-4 and PD-L1 monolithic antibody fusion composition;
KN046 has conducted nearly 20 phased clinical trials in Australia and China covering more than 10 types of tumors, including non-small cell lung cancer, triple-yin breast cancer, esophageal squamous cancer, liver cancer and pancreatic cancer, and the results show that patients have the advantage of survival benefits.
FDA approved KN046's direct entry into Phase II clinical trials in the United States based on clinical trial results obtained in Australia and China, and in September 2020 granted KN046 the qualification of orphan drugs for the treatment of thymus epitheliote tumors.
two registered clinical trials of KN046 are currently under way.
note: There are deletions in the original text